In the clinical Phase Ia dose escalation study, tumor biopsies were scheduled at screening and after dosing on the first day of the second treatment cycle (C2D1) to assess the modulation of Met-EF1α at expected steady-state. The gene discussed is EEF1A1; the disease is neoplasm.